Replimune Group

Replimune Group’s stock rose to a 52-week high of $15.72 and is currently trading at $15.69, implying a market capitalization of about $1.47 billion. Over the past year the share gained 174.3%, while InvestingPro warns the stock may currently be trading above its fair value. Options data suggest a potential price move of roughly 5.6% ahead of the quarterly results. Several analysts (Wedbush, Leerink, Cantor Fitzgerald) raised their valuations following the FDA approval of Tudriqev and positive prospects for RP-1 in combination with nivolumab. » Más en de.investing.com

The options market implies an expected 5.6% price move for Replimune Group around the quarterly results expected on August 21; the exact publication date has not yet been confirmed. Historical comparisons show that actual stock reactions to previous quarterly reports sometimes differed markedly from the implied moves, with both larger gains and sizable declines. » Más en de.investing.com

Replimune shares climbed intraday by 15.3% to $13.90, reaching a new 52-week high. On August 6 the FDA granted accelerated approval for TUDRIQEV in combination with nivolumab for the treatment of advanced, unresectable cutaneous melanoma after prior anti‑PD‑1 therapy. At the same time the company placed a guaranteed $150 million capital increase (price $12.06/share) with expected net proceeds of about $140.5 million to bolster the balance sheet for the commercial launch; analysts raised price targets and valuations. Management now faces the task of showing a credible path from approval to revenue generation while investors price in the anticipated commercial opportunities for TUDRIQEV. » Más en de.investing.com